In a blog post, the leading trade group for the US pharmaceutical industry has slammed a recent report from the Initiative for Medicines, Access & Knowledge (I-MAK).
While I-MAK accuses biotech companies of preventing competition and innovation, the Pharmaceutical Research and Manufacturers of America (PhRMA) argues that “new patents do not extend old patents, and they do not prevent competitors from launching new products.”
The group said that America’s intellectual property system in fact “paves the way for generic and biosimilar competition,” highlighting that more than 90% of current US prescriptions are filled by generics.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze